SOL-R, the second registrational trial of AXPAXLI™ in wet AMD, remains on track for topline data in 1H 2027
Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R
Seeking Alpha / 7 hours ago 1 Views
Seeking Alpha / 7 hours ago 1 Views
SOL-R, the second registrational trial of AXPAXLI™ in wet AMD, remains on track for topline data in 1H 2027
Comments